CD8A and rheumatoid arthritis: In addition to CD8+CD28− Tregs, an anti-CD3 monoclonal antibody (mAb) has been shown to activate peripheral blood mononuclear cells (PBMC) from RA patients to induce CD8+Foxp3+ Tregs that inhibit IL-17 production [22].